Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management - PubMed
5 hours ago
- #MASH
- #personalized medicine
- #MASLD
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease globally.
- Recent FDA approvals of resmetirom and semaglutide mark a transformative era in MASH management.
- Challenges include the lack of dynamic biomarkers, reliance on biopsies, high placebo response rates, and disease heterogeneity.
- Emerging approaches like noninvasive tests and multi-omic profiling aim to improve patient selection and monitoring.
- A personalized care framework integrates lifestyle interventions, incretin-based therapies, and liver-directed agents to mitigate disease progression and cardiometabolic risks.